1 week Ago By ABMN Staff
Vanguard Group Inc. increased its position in shares of Disc Medicine, Inc. ( NASDAQ:IRON – Free Report ) by 1.
8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,068,246 shares of the company’s stock after purchasing an additional 18,716 shares during the period. Vanguard Group Inc.
’s holdings in Disc Medicine were worth $67,727,000 as of its most recent filing with the Securities and Exchange Commission. Several other institutional investors have also added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Disc Medicine during the fourth quarter worth $235,000.
Virtu Financial LLC bought a new position in Disc Medicine during the fourth quarter worth about $309,000. Teacher Retirement System of Texas raised its stake in Disc Medicine by 8.9% in the 4th quarter.
Teacher Retirement System of Texas now owns 4,857 shares of the company’s stock worth $308,000 after purchasing an additional 396 shares in the last quarter. Intech Investment Management LLC boosted its holdings in Disc Medicine by 69.8% in the 4th quarter.
Intech Investment Management LLC now owns 7,890 shares of the company’s stock valued at $500,000 after purchasing an additional 3,243 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Disc Medicine during the 4th quarter worth approximately $5,579,000.
83.70% of the stock is currently owned by institutional investors. Disc Medicine Trading Down 9.
0 % IRON opened at $35.23 on Friday. The company has a market cap of $1.
22 billion, a P/E ratio of -8.85 and a beta of 0.77.
The company’s 50 day moving average is $51.20 and its 200-day moving average is $55.58.
Disc Medicine, Inc. has a 1-year low of $25.64 and a 1-year high of $68.
73. Insider Buying and Selling In related news, insider Pamela Stephenson sold 3,137 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $54.
58, for a total value of $171,217.46. Following the completion of the transaction, the insider now owns 69,529 shares in the company, valued at $3,794,892.
82. This trade represents a 4.32 % decrease in their position.
The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink . Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of Disc Medicine stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.
58, for a total transaction of $87,873.80. Following the sale, the chief operating officer now owns 40,555 shares in the company, valued at approximately $2,213,491.
90. This represents a 3.82 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Insiders have sold 361,690 shares of company stock worth $19,648,094 in the last 90 days. Insiders own 4.
24% of the company’s stock. Wall Street Analyst Weigh In IRON has been the subject of a number of analyst reports. Scotiabank lifted their price target on shares of Disc Medicine from $73.
00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, March 3rd. Stifel Nicolaus upped their target price on Disc Medicine from $90.
00 to $94.00 and gave the company a “buy” rating in a research report on Friday, January 24th. HC Wainwright restated a “buy” rating and issued a $118.
00 price target on shares of Disc Medicine in a research report on Tuesday, January 21st. Cantor Fitzgerald boosted their price target on Disc Medicine from $99.00 to $132.
00 and gave the company an “overweight” rating in a research note on Tuesday, March 18th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research note on Friday, March 7th.
Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Disc Medicine presently has a consensus rating of “Buy” and a consensus price target of $93.
80. View Our Latest Stock Analysis on IRON About Disc Medicine ( Free Report ) Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Further Reading Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. ( NASDAQ:IRON – Free Report ).
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter ..
